Home » Joseph Puglisi

Joseph Puglisi

Nov 21, 2003
Premium

PTC Therapeutics said this week that it has named Joseph Puglisi to its scientific advisory board.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Twisting the Results

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Quickly, Quickly

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

'Right to Try' Heads Toward Law

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

This Week in Genome Research

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Jun
19
Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

What's Popular?

In Gene Silencing/Gene Editing

  1. Stanford Researchers Develop Multiplexed, Precision Genome Editing Tool for Yeast

    Premium

  2. Gene Editing Startup Beam Therapeutics Launches With $87M in Series A Funds

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.